Annals of Emergency Medicine
Volume 54, Issue 1 , Pages 114-116 , July 2009

Albumin Administration in the Management of Critically Ill Patients: Is It Safe?

  • Lauralyn McIntyre, MD, FRCPC, MSc

      Affiliations

    • University of Ottawa, Department of Medicine (Division of Critical Care), Ottawa Health Research Institute, Center for Transfusion and Critical Care Research, Ottawa Hospital, Ottawa, Ontario, Canada
    • ,
  • Robert S. Green, MD, BSc, FRCPC, DABEM

      Affiliations

    • Dalhousie University, Department of Emergency Medicine, Department of Internal Medicine, Division of Critical Care Medicine, Halifax, Nova Scotia, Canada

References 

  1. Schortgen F, Deye N, Brochard L, et al. Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med. 2004;30:2222–2229
  2. Miletin M, Steward T, Norton PG. Influence on physicians' choices of intravenous colloids. Intensive Care Med. 2002;28:917–924
  3. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256
  4. Brunkhorst F, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–139
  5. Marik PE, Iglesias J. Would the colloid detractors please sit down!. Crit Care Med. 2000;28:2652–2654
  6. Vercueil A, Grocott MP, Mythen MG. Physiology, pharmacology, and rationale for colloid administration for the maintenance of effective hemodynamic stability in critically ill patients. Transfus Med Rev. 2005;19:93–109
  7. American Thoracic Society. Evidence-based colloid use in the critically ill: American Thoracic Society consensus statement. Am J Respir Crit Care Med. 2004;170:1247–1259
  8. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials (Cochrane Injuries Group Albumin Reviewers). BMJ. 1998;317:235–240
  9. Roberts I, Edwards P, McLelland B. More on albumin (Use of human albumin in UK fell substantially when systematic review was published). BMJ. 1999;318:1214–1215
  10. Safe Study Investigators. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007;357:874–884
  11. Cook D. Is albumin safe?. N Engl J Med. 2004;350:2294–2296
  12. Fan E, Stewart TE. Albumin in critical care: SAFE, but worth its salt?. Crit Care. 2004;8:297–299
  13. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008;29:109–113
  14. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008;66:1909–1914
  15. Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Serv Res. 2002;2:18
  16. Gotzsche PC, Hrobjartsson A, Johansen HK, et al. Ghost authorship in industry-initiated randomised trials. PLoS Med. 2007;4:e19

PII: S0196-0644(08)01584-9

doi: 10.1016/j.annemergmed.2008.07.047

Annals of Emergency Medicine
Volume 54, Issue 1 , Pages 114-116 , July 2009

Article Tools